Abstract Background: Antibody-drug conjugates (ADCs) are increasingly prescribed in anti-tumor treatment; however, metabolism and nutrition disorders (MNDs) during ADC therapy remain insufficiently characterized. We evaluated short-term nutritional changes after inotuzumab ozogamicin (INO) in a pediatric relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) cohort and separately assessed ADC-associated MND reporting signals in the FDA Adverse Event Reporting System (FAERS).